The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

Abstract Background Glioblastoma (GBM) is a fatal brain tumor, lacking effective treatment. Epidermal growth factor receptor (EGFR) is recognized as an attractive target for GBM treatment. However, GBMs have very poor responses to the first- and second-generation EGFR inhibitors. The third-generatio...

Full description

Bibliographic Details
Main Authors: Xuejiao Liu, Xiangyu Chen, Lin Shi, Qianqian Shan, Qiyu Cao, Chenglong Yue, Huan Li, Shengsheng Li, Jie Wang, Shangfeng Gao, Mingshan Niu, Rutong Yu
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
GBM
AZD9291
EGFR/ERK signaling pathway
Cell proliferation
Online Access:http://link.springer.com/article/10.1186/s13046-019-1235-7

Internet

http://link.springer.com/article/10.1186/s13046-019-1235-7

Similar Items